

MAGLUMI CA 72-4 (CLIA)



130201015M



100



**Shenzhen New Industries
Biomedical Engineering Co., Ltd**
4F, Wearn's Tech Bldg,
Science & Industry Park,
Nanshan, Shenzhen, 518057 CHINA
Tel. + 86-755-86028224
Fax. + 86-755-26654850



Lotus Global Co., Ltd
15 Alexandra Road
London
NW8 0DP
UK
Tel. + 44-20-75868010
Fax. + 44-20-79006187



FOR PROFESSIONAL USE ONLY

Store at 2-8°C



COMPLETELY READ THE INSTRUCTIONS BEFORE
PROCEEDING



SYMBOLS EXPLANATIONS



Authorized Representative in Europe




Manufacturer



Attention. See Instructions For Use



Contents of kit



In vitro diagnostic medical device
(In vitro diagnostic use)




Lot number



Catalogue Code



Expiry date (Use by...)



Temperature limitation
(store at 2-8°C)



Number of tests



Keep away from direct sunlight



Keep upright for storage

INTENDED USE

The kit has been designed for the quantitative determination of Cancer Antigen 72-4 (CA 72-4) in human serum.

The method can be used for samples over the range of 0-500 IU/ml.

The test has to be performed on the MAGLUMI chemiluminescence immunoassay (CLIA) fully auto analyzer (Including MAGLUMI 1000, MAGLUMI 2000, MAGLUMI 2000 Plus and new developed models).

SUMMARY AND EXPLANATION OF THE TEST

Tumor-associated glycoprotein-72 (TAG-72) is a high molecular weight, mucin-like, glycoprotein complex (220-400kD) that was originally defined by B72.3 antibody reactivity. The Cancer Antigen 72-4 (CA72-4) antigenic determinant is located on TAG-72. CA72-4 is expressed in a wide range of human carcinomas but has little or no staining in lymphomas, mesotheliomas, neural tumors, sarcomas, or benign tumors. CA72-4 is generally not found in normal adult tissue, with the exception of secretory endometrium, but was detected in fetal colon, esophagus, and stomach, 2, 3. On fine needle aspirants of breast masses, B72. Antibody was shown to react with 96% of malignant cases (26/27) and only 4% benign cases (1/23). It has also been reported that 77% of primary ovarian cancers (40/55) and 71% of metastatic ovarian cancers (22/31) stained positive with B72.3 in at least 5% of cells, while only 4% of benign ovarian tumors did (1/27). No staining was seen in normal ovarian tissue. In another study, B72.3 antibody showed reactivity in 92% of adenocarcinomas (36/39) and no reactivity in mesotheliomas (0/68).

PRINCIPLE OF THE TEST

Sandwich immunoluminometric assay;

Use an anti-CA72-4 monoclonal antibody to label ABEI, and use another monoclonal antibody to label FITC. Sample, Calibrator or Control, with ABEI Label, FITC Label and magnetic microbeads coated with anti-FITC are mixed thoroughly and incubated at 37 °C, forming a sandwich; after sediment in a magnetic field, decant the supernatant, then cycle washing for 1 time. Subsequently, the starter reagents are added and a flash chemiluminescent reaction is initiated. The light signal is measured by a photomultiplier as RLU within 3 seconds and is proportional to the concentration of CA72-4 present in controls or samples.



KIT COMPONENTS

Material Supplies

Reagent Integral for 100 determinations	
Nano magnetic microbeads: TRIS buffer, 1.2% (W/V), 0.2%NaN ₃ , coated with sheep anti-FITC polyclonal antibody.	2.5ml
Calibrator Low: bovine serum, 0.2%NaN ₃	3.0ml
Calibrator High: bovine serum, 0.2%NaN ₃	3.0ml
FITC Label: anti-CA72-4 monoclonal antibody labeled FITC contains BSA, 0.2%NaN ₃ .	10.5ml
ABEI Label: anti-CA72-4 monoclonal antibody labeled ABEI contains BSA, 0.2%NaN ₃ .	10.5ml
All reagents are provided ready-to-use.	

Reagent Vials in kit box	
Internal Quality Control: containing BSA, 0.2%NaN ₃ . (target value refer to Quality Control Information date sheet)	2.0ml

Accessories Required But Not Provided

MAGLUMI Reaction Module	REF: 630003
MAGLUMI Starter 1+2	REF: 130299004M
MAGLUMI Wash Concentrate	REF: 130299005M
MAGLUMI Light Check	REF: 130299006M



Preparation of the Reagent Integral

Before the sealing is removed, gentle and careful horizontal shaking of the Reagent Integral is essential (avoid foam formation!) Re- move the sealing and turn the small wheel of the magnetic micro- beads compartment to and fro, until the color of the suspension has changed into brown. Place the Integral into the reagent area and let it stand there for 30 min. During this time, the magnetic micro-beads are automatically agitated and completely resuspended.

Do not interchange integral component from different reagents or lots!

Storage and Stability

- Sealed: Stored at 2-8 °C until the expiry date.
- Opened: Stable for 4 weeks. To ensure the best kit performance, it is recommended to place opened kits in the refrigerator if it's not going to be used on board during the next 12 hours.



- Keep upright for storage



- Keep away from direct sunlight

CALIBRATION AND TRACEABILITY

1) Traceability

To perform an accurate calibration, we have provided the test calibrators standardized against the SNIBE internal reference substance.

Calibrators in the Reagent Kit are from Fitzgerald.

2) 2-Point Recalibration

Via the measurement of calibrators, the predefined master curve is adjusted (recalibrated) to a new, instrument-specific measurement level with each calibration.

3) Frequency of Recalibration

- After each exchange of lots (Reagent Integral or Starter Reagents).
- Every 2 weeks and/or each time a new Integral is used (recommendation).
- After each servicing of the MAGLUMI Fully Auto analyzer.
- If controls are beyond the expected range.

SPECIMEN COLLECTION AND PREPARATION

Sample material: serum

Collect samples using standard procedures.

Store at 2-8 °C below - 20 °C

Avoid repeated freezing and thawing cycles, stored samples should be thoroughly mixed prior to use (Vortex mixer).

Please ask local representative of SNIBE for more details if you have any doubt.

Vacuum Tubes

- Blank tubes are recommended type for collecting samples.
- Please ask SNIBE for advice if special additive must be used in sample collecting.

067120525-v1.0-EN

Specimen Conditions

- Do not use specimens with the following conditions:
 - heat-inactivated specimens;
 - Cadaver specimens or body fluids other than human serum;
 - Obvious microbial contamination.
- Use caution when handling patient specimens to prevent cross contamination. Use of disposable pipettes or pipette tips is recommended.
- Inspect all samples for bubbles. Remove bubbles with an applicator stick prior to analysis. Use a new applicator stick for each sample to prevent cross contamination.
- Serum specimens should be free of fibrin, red blood cells or other particulate matter.
- Ensure that complete clot formation in serum specimens has taken place prior to centrifugation. Some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If the specimen is centrifuged before a complete clot forms, the presence of fibrin may cause erroneous results.

Preparation for Analysis

- Patient specimens with a cloudy or turbid appearance must be centrifuged prior to testing. Following centrifugation, avoid the lipid layer (if present) when pipetting the specimen into a sample cup or secondary tube.
- Specimens must be mixed **thoroughly** after thawing by **low** speed vortexing or by gently inverting, and centrifuged prior to use to remove red blood cells or particulate matter to ensure consistency in the results. Multiple freeze-thaw cycles of specimens should be avoided.
- All samples (patient specimens or controls) should be tested within 3 hours of being placed on board the MAGLUMI System. Refer to the SNIBE service for a more detailed discussion of onboard sample storage constraints.

Storage

- If testing will be delayed for more than 8 hours, remove serum or plasma from the serum or plasma separator, red blood cells or clot. Specimens removed from the separator gel, cells or clot may be stored up to 24 hours at 2-8°C.
- Specimens can be stored up to 30 days frozen at -20°C or colder.

Shipping

Before shipping specimens, it is recommended that specimens be removed from the serum or plasma separator, red blood cells or clot. When shipped, specimens must be packaged and labeled in compliance with applicable state, federal and international regulations covering the transport of clinical specimens and infectious substances. Specimens must be shipped frozen (dry ice). Do not exceed the storage time limitations identified in this section of the package insert.

WARNING AND PRECAUTIONS FOR USERS



°C: 24 hours for use in diagnostic procedures only.

- Package insert instructions must be carefully followed. Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in this package insert.

Safety Precautions

CAUTION: This product requires the handling of human specimens.

- The calibrators in this kit are prepared from bovine serum products. However, because no test method can offer complete assurance that HIV, Hepatitis B Virus or other

- infectious agents are absent; these reagents should be considered a potential biohazard and handled with the same precautions as applied to any serum or plasma specimen.
- All samples, biological reagents and materials used in the assay must be considered potentially infectious. They should therefore be disposed of in accordance with the prevailing regulations and guidelines of the agencies holding jurisdiction over the laboratory, and the regulations of each country. Disposable materials must be incinerated; liquid waste must be decontaminated with sodium hypochlorite at a final concentration of 5% for at least half an hour. Any materials to be reused must be autoclaved using an overkill approach (USP 24, 2000, p.2143). A minimum of one hour at 121 °C is usually considered adequate, though the users must check the effectiveness of their decontamination cycle by initially validating it and routinely using biological indicators.
- It is recommended that all human sourced materials be considered potentially infectious and handled in accordance with the OSHA Standard on Blood borne Pathogens 13. Biosafety Level 214 or other appropriate biosafety practices should be used for materials that contain or are suspected of containing infectious agents.
- This product contains Sodium Azide; this material and its container must be disposed of in a safe way.
- Safety data sheets are available on request.

Handling Precautions

- Do not use reagent kits beyond the expiration date.
- Do not mix reagents from different reagent kits.
- Prior to loading the Reagent Kit on the system for the first time, the microbeads requires mixing to re-suspend microbeads that have settled during shipment.
- For micro-beads mixing instructions, refer to the KIT COMPONENTS, Preparation of the Reagent Integral section of this package insert.
- To avoid contamination, wear clean gloves when operating with a reagent kit and sample.
- Over time, residual liquids may dry on the kit surface; please pay attention to the silicon film still exists on the surface of the kit.
- For a detailed discussion of handling precautions during system operation, refer to the SNIBE service information.

TEST PROCEDURE

To ensure proper test performance, strictly adhere to the operating instructions of the MAGLUMI Fully Auto analyzer. Each test parameter is identified via a RFID tag on the Reagent Integral. For further information please refer to the MAGLUMI Chemiluminescence Analyzer Operating Instructions.

80µl	Sample, calibrator or controls
+80µl	ABEI Label
+80µl	FITC Label
+20µl	Nano magnetic microbeads
30 min	Incubation
400µl	Cycle washing
3 s	Measurement

DILUTION

Sample dilution by analyzer is not available in this reagent kit. Samples with concentrations above the measuring range can be diluted manually. After manual dilution, multiply the result by the dilution factor. Please choose applicable diluents or ask SNIBE for advice before manual dilution must be processed.

QUALITY CONTROL

- Observe quality control guidelines for medical laboratories

- Use suitable controls for in-house quality control. Controls should be run at least once every 24 hours when the test is in use, once per reagent kit and after every calibration. The control intervals should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined ranges. Each laboratory should establish guidelines for corrective measures to be taken if values fall outside the range.

LIMITATIONS OF THE PROCEDURE

1) Limitations

Assay results should be utilized in conjunction with other clinical and laboratory data to assist the clinician in making individual patient management decisions.

A skillful technique and strict adherence to the instructions are necessary to obtain reliable results.

Procedural directions must be followed exactly and careful technique must be used to obtain valid results. Any modification of the procedure is likely to alter the results.

Bacterial contamination or repeated freeze-thaw cycles may affect the test results.

2) HAMA

Patient samples containing human anti-mouse antibodies (HAMA) may give falsely elevated or decreased values. Although HAMA-neutralizing agents are added, extremely high HAMA serum concentrations may occasionally influence results.

3) Interfering Substances

No interference with test results is seen by concentrations of bilirubin<0.06mg/ml, haemoglobin<16mg/dl or triglycerides<12.5mg /ml.

4) High-Dose Hook

No high-dose hook effect was seen for CA72-4 concentrations up to 10,000 IU/ml.

RESULTS

1) Calculation of Results

The analyzer automatically calculates the CA72-4 concentration in each sample by means of a calibration curve which is generated by a 2-point calibration master curve procedure. The results are expressed in IU/ml. For further information please refer to the MAGLUMI Chemiluminescence Analyzer Operating Instructions.

2) Interpretation of Results

- Results of study in clinical centers with group of individuals, 95% of the results were :< 6IU/ml.
- Results may differ between laboratories due to variations in population and test method. If necessary, each laboratory should establish its own reference range.

PERFORMANCE CHARACTERISTICS

1) Precision

Intra-assay coefficient of variation was evaluated on 3 different levels of control serum repeatedly measured 20 times in the same run, calculating the coefficient of variation.

Intra-assay precision			
Control	Mean(IU/ml)	SD(IU/ml)	CV%
Level 1	8.76	0.92	10.26
Level 2	14.32	1.35	9.27
Level 3	52.84	2.49	4.73

Inter-assay coefficient of variation was evaluated on three batches of kits. Repeatedly measured 3 different levels of control serum 21 times, calculating the coefficient of variation.

Inter-assay precision			
Control	Mean(IU/ml)	SD(IU/ml)	CV%
Level 1	7.83	0.76	9.72
Level 2	14.41	1.29	8.96

Level 3	48.63	4.38	9.02
---------	-------	------	------

2) Analytical Sensitivity

The sensitivity is defined as the concentration of CA72-4 equivalent to the mean RLU of 20 replicates of the zero standard plus two standard deviations corresponding to the concentration from the standard curve. The sensitivity is typically less than 1.5IU/ml.

3) Specificity

The specificity of the CA72-4 assay system was assessed by measuring the apparent response of the assay to various potentially cross reactive analytes.

Compound	Concentration	Cross reactivity
CA125	800IU/ml	0.6%
CA15-3	800IU/ml	0.7%
CA19-9	800IU/ml	0.7%

4) Recovery

Consider calibrator high of known concentration as a sample, dilute it by 1:2 ratio with diluents, and measure its diluted concentration for 10 times. Then calculate the recovery of measured concentration and expected concentration. The recovery should be within 90% -110%.

Expected	Mean Measuring	Recovery
125.371IU/ml	124.106IU/ml	98%

5) Linearity

Use CA72-4 calibrator to prepare the six-point standard curve, measuring all points' RLU except point A, and then do four-parameter linear fitting in double logarithm coordinate, the absolute linear correlation coefficient(r) should be bigger than 0.9800.

Calibrator Point	Concentration IU/ml	Absolute linear correlation coefficient (r)
A	0	
B	6	r=0.9804
C	50	
D	100	
E	200	
F	500	

6) Method comparison

A comparison of MAGLUMI CA72-4(y) with a commercially available CA72-4 test (x) using clinical samples gave the following correlations (IU/ml):

Linear regression

$$y = 0.96x + 5.45$$

$$r = 0.955$$

$$S_{y.x} = 7.83$$

Number of samples measured: 142

The sample concentrations were between 4.53 and 427.75IU/ml.

REFERENCES

1. CA 724 serum marker--a new tool in the management of carcinoma patients. *Cancer Invest.* 1995; 13(2):227-38. Review.
2. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. *Is Markers.* 2000; 16(3-4):105-10.
3. Tumor-associated glycoprotein-724 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study. *Cancer.* 1991 Dec 1; 68(11):2443-50.
4. Mattar R, Andrade CR, Difavero GM, et al. Preoperative serum levels of CA 724, CEA, CA 1929 and alpha2fetoprotein in

patients with gastric cancer. *Rev;Ho sp Clin FacM ed Sao Paulo,* 2002; 57 (1) :89.

5. Gaspar MJ, Aribas I, Coca MC, et al, Prognostic value of carcinoembryonic antigen CA19-9 and CA72-4 in gastric carcinoma. *Tumor Bio I,* 2001; 22 (5):318.
6. David w; Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. *Ann Surg Oncol.* 2007 Feb; 14(2):417-23.
7. Mical o; Adipose tissue concentrations of persistent organic pollutants and the risk of prostate cancer. *J Occup Environ Med.* 2006 Jul; 48(7):700-7.
8. Hasholzner U; Significance of serum CA72-4 in the differential diagnosis between benign and malignant lung diseases; *cancer magazine--2002/1.*
9. Stieber P; Expression of Serum TPS and CA72-4 in Patients with Breast Cancer and Its Clinical Significance; *college paper--2004/2.*
10. Glimelius B; Value of combined multiple tumor markers in the diagnosis of ovarian tumor; *cancer paper--2007/2.*
11. Tokoo M; Clinical value of serum CA72-4 assay in the patients with recurrent breast carcinoma; *tumor clinic--2003/6.*
12. Glimelius B; Diagnostic significance of multiple tumor marker detection in hydropleuritis; *clinic tumor--2004/6.*